The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Data ReadoutDeramiocelPositive

AI Analysis

Summary

Capricor Therapeutics announced publication of HOPE-3 trial data for Deramiocel in Duchenne Muscular Dystrophy in The Lancet. The data readout represents a significant milestone for the cell-based therapeutic program.

Clinical Trial Data

Importance:6/10

Sentiment:

0.50

clinical trial datarare diseasecell therapyexosome therapypublication

Related Companies

$CAPR

Read the original article

Published by Drugs.com Clinical Trial Results on July 29, 2026 2:07 AM

Read Original